Clinical Trial Update: Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study [Phase 3]

View source ↗

Summary

Phase 3 trial comparing bendamustine plus rituximab to R-CVP or R-CHOP in first-line advanced indolent non-Hodgkin's lymphoma or mantle cell lymphoma; results p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• R-CHOP
• R-CVP (rituximab, cyclophosphamide, vincristine, prednisone)
• bendamustine hydrochloride plus rituximab (bendamustine and rituximab)

Snippet

Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. | Conditions: Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma | Phase 3 | Status: COMPLETED | Results posted: 2014-04-28